Stelara IL-12/IL-23 Binding Assays

BioOutsource has extensive experience in the design, optimisation, qualification and implementation of novel binding assays suitable for the assessment of a range of monoclonal antibody therapeutics.  This provides a strong basis for the development of innovative solutions to the quantification, assessment and comparison of Stelara (Ustekinumab) binding assays.  Binding assays are developed to characterise the primary action of Fab binding affinity for IL-12 and assays are also available for IL-12p40, IL-12p80 and IL-23.  Performance of binding assays to the Fc region can be developed using our standard IgG1 Fc-binding platform approach.

Interaction studies are fundamental to understanding the function of monoclonal antibodies as therapeutic molecules.  IL-12 binding assays can be performed using a number of different assay platforms, and each platform method can utilise different assay designs.  BioOutsource has developed the following Stelara Fab binding assays:

IL-12, IL-12p40, IL-12p80 and IL-23 Binding ELISAs

BioOusource offers IL-12, IL-12p40, IL-12p80 and IL-23 binding assays using a traditional ELISA platform. The relative binding of the biosimilar as a percentage of a designated reference standard lot is reported along with comprehensive parallelism assessments.  BioOutsource works closely with our clients to ensure the assay method meets the requirements of your study.